VP-102: Clinical Trials

4 trials of VP-102, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 recruiting. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Completed 2, Active not recruiting 1, Recruiting 1

Follow VP-102: new trials by email Literature Review of VP-102 trials Research Report on VP-102

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan) - Common Warts, Common Warts (Verruca Vulgaris)
Phase 3RecruitingVerrica Pharmaceuticals Inc.3002026-06-152026-09-03
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
VP-102, Vehicle - Common Warts, Common Warts (Verruca Vulgaris)
Phase 3Active not recruitingVerrica Pharmaceuticals Inc.3022025-12-172026-10-23
Cantharidin Application in Molluscum Patients-1
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102 - Molluscum Contagiosum
Phase 3CompletedVerrica Pharmaceuticals Inc.2662018-03-212022-01-11
Cantharidin Application in Molluscum Patients
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102 - Molluscum Contagiosum
Phase 3CompletedVerrica Pharmaceuticals Inc.2622018-02-142021-12-14

Conditions studied

Cellulitis (2)  ·  Molluscum Contagiosum (2)  ·  Poxviridae Infections (2)  ·  Skin Diseases (2)  ·  Skin Diseases, Viral (2)  ·  Warts (2)

Sponsors

Verrica Pharmaceuticals Inc. (4)

Countries

United States (4)  ·  Japan (1)

Top investigators

Lawrence Eichenfield, MD (2)

Results publications

PMID 32965495, PMID 33599960, PMID 34976290